Furthermore, considering UBE2C’s significant role in modulating the activity of immune and stromal cells within the HCC microenvironment, combination therapies that incorporate immune checkpoint inhibitors or stromal-targeting agents may synergistically augment the effectiveness of UBE2C inhibitors. The gene discussed is UBE2C; the disease is hepatocellular carcinoma.